Suchergebnisse - "Carlo-Stella, Carmelo"

PubPharm (258)

1

Deep learning-based optimization of field geometry for total marrow irradiation delivered with volumetric modulated arc therapy

enthalten in: Medical physics | 2024

von Lambri, N. | Longari, G. | Loiacono, D. | +17

2

Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma : long-term efficacy and safety from the phase II LOTIS-2 study

enthalten in: Haematologica | 2024

von Caimi, P. | Ai, W. | Alderuccio, J. | +13

3

Deep learning and atlas-based models to streamline the segmentation workflow of total marrow and lymphoid irradiation

enthalten in: La Radiologia medica | 2024

von Dei, D. | Lambri, N. | Crespi, L. | +13

4

In relapsed or refractory diffuse large B-cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine

enthalten in: EJHaem | 2024

von Caimi, P. | Hamadani, M. | Carlo-Stella, C. | +10

5

Baseline circulating tumour DNA and interim PET predict response in relapsed/refractory classical Hodgkin lymphoma

enthalten in: British journal of haematology | 2024

von Calabretta, E. | di Trani, M. | Corrado, F. | +10

6

Deep learning and atlas-based models to streamline the segmentation workflow of total marrow and lymphoid irradiation

enthalten in: La Radiologia medica | 2024

von Dei, D. | Lambri, N. | Crespi, L. | +13

7

Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas

enthalten in: British journal of haematology | 2024

von Dodero, A. | Bramanti, S. | Di Trani, M. | +14

8

Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial

enthalten in: Blood advances | 2024

von Hamadani, M. | Spira, A. | Zhou, X. | +16

9

Outcome of High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma after Different Numbers of Salvage Regimens

enthalten in: Cells | 2024

von Mariotti, J. | Ricci, F. | Giordano, L. | +7

10

PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2024

von Alderuccio, J. | Reis, I. | Hamadani, M. | +18

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[26]